Prothena Posts Q1 Profit on $50M Novo Nordisk Milestone Payment
Prothena posted a Q1 2026 profit as a $50 million milestone payment from Novo Nordisk boosted revenue and improved its cash outlook for the year.
Key Numbers
Prothena Corporation (NASDAQ: PRTA) reported a profit for the first quarter of 2026, driven by a $50 million milestone payment from its partner Novo Nordisk. The payment significantly boosted revenue and improved the company's full-year cash outlook. Exact net income and earnings per share figures were not disclosed.
Key Financial Results
| Metric | Q1 2026 |
|---|---|
| Revenue | $50 million (from milestone payment) |
| Net Income | Profit (figure not disclosed) |
| EPS | Not disclosed |
| Cash Position | Improved outlook for 2026 |
Highlights from the Release
Prothena stated that the Novo Nordisk milestone payment was the primary driver of Q1 revenue. The company also noted that the payment strengthens its financial position and supports continued development of its therapeutic programs.
Future Guidance
Prothena did not provide specific quarterly guidance but improved its full-year 2026 cash outlook, indicating better financial stability.
Stock Impact
No direct stock reaction was mentioned, but positive news could support investor confidence in the near term.
What This Means for Investors
Prothena's results demonstrate its ability to generate revenue from strategic partnerships, reducing reliance on external funding. However, the focus remains on the progress of its key therapeutic programs for future growth assessment.
Frequently Asked Questions
Found this useful? Share it